Pharmaceuticals
U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
- Submission based on data from the Phase III PRIMA clinical study that demonstrated clinically-meaningful outcomes of niraparib maintenance treatment in the first-line setting regardless of biomarker status - The application is being reviewed under the FDA's Real-Time Oncology Review pilot pr...
2020-02-24 22:00
1348
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China
SUZHOU, China and ROCKVILLE, MD., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has receive...
2020-02-24 22:00
2466
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biotechnology comp...
2020-02-24 08:00
6190
Nearly VND 20 billion sponsored by Vingroup for research projects on response to novel coronavirus
HANOI, Vietnam, Feb. 21, 2020 /PRNewswire/ -- 3 units funded by Vingroup
Innovation Foundation (VINIF) include The Company for Vaccine and Biological
Production No.1 (Vabiotech), Pasteur Institute inHo Chi Minh City and Institute
of Preventive Medicine and Public Health.
2020-02-21 10:09
3610
VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
AUSTIN, Texas, Feb. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2019. Volition management will host a conference call tomorrow,February 21, at 8:30 a.m. U.S. Easte...
2020-02-21 05:10
10127
StoneWise AI-driven Drug Discovery Platform: Investigation and Repurpose of Nucleoside-based RNA Polymerase Inhibitors and Their Potential Use in COVID-19 Infection Treatment
BEIJING, Feb. 20, 2020 /PRNewswire/ -- In a campaign to screen drugs for the treatment of COVID-19, the disease caused by SARS-CoV-2, StoneWise, a company specialized in applying artificial intelligence to innovative drug design solutions for innovative drug R&D enterprises and institutions, has ...
2020-02-20 20:04
1431
Sihuan Pharmaceutical Announces Acquisition of All Interests and Intellectual Property Rights of Plazomicin, A New Generation of Aminoglycoside Antibiotics in the Greater China Region
HONG KONG, Feb. 20, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Xuanzhu (HK) Biopharmaceutical Limited (''Xuanzhu''), a wholly-owned subsidiary of the...
2020-02-20 18:59
13208
111 Partners with Financial Institutions in Battle Against Coronavirus
SHANGHAI, Feb. 20, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI, "111" or the "Company") has announced that it will leverage its knowhow and technology in the battle against the novel coronavirus (COVID-19) public health crisis, through partnerships with some ofChina's leading financial institution...
2020-02-20 17:00
5368
NeuroVive Pharmaceutical AB Year End Report January - December 2019
STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 * NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroVive compl...
2020-02-19 16:08
6351
VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunctio...
2020-02-19 05:10
10271
Volition Unveils Its Epigenetic Toolbox
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that research on its Nu.Q(TM) Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform...
2020-02-18 21:30
8644
Ally Bridge Group Leads US$70 million Investments in Two Israeli Life Science Companies over the Last 2 Months
TEL AVIV, Israel, HONG KONG and NEW YORK, Feb. 18, 2020 /PRNewswire/ — Ally Bridge Group ("ABG"), a leading global life science investment group, has announced that it recently ledUS$70 million investments in two Israeli life science companies over the last 2 months. Each of the two companies is ...
2020-02-18 21:30
1884
WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader
SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that WuXi Vaccines, its joint venture with Shanghai ...
2020-02-18 18:42
2709
Sihuan Pharmaceutical: Production Approval Granted For Rivastigmine Hydrogen Tartrate Capsule, The First Drug Passing Consistency Evaluation And Levetiracetam Tablet And The First Registration Approval Granted For Midazolam Oromucosal Solution
HONG KONG, Feb. 18, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that rivastigmine hydrogen tartrate capsule and levetiracetam tablet developed by the Group...
2020-02-18 18:07
7003
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
HANGZHOU, China and SHAOXING, China, Feb. 18, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the application for in-house developed Category 1 Drug ASC41 for clinical trials of NASH indication has been accepted byChina's National Medical Products Administration (NMPA)...
2020-02-18 08:00
3423
A New Expert Consensus Publication Provides Practical Guidance on the Use of Omega-3 Fatty Acids in Parenteral Nutrition
BAD HOMBURG, Germany, Feb. 17, 2020 /PRNewswire/ -- Fresenius Kabi, a global leader in clinical nutrition, announces that the Journal of Parenteral and Enteral Nutrition (JPEN) has recently published "Lipids in Parenteral Nutrition: Translating Guidelines into Clinical Practice".[1] The publicati...
2020-02-17 17:00
5228
Eirgenix Receives Approval from Japan's PMDA
TAIPEI, Feb. 14, 2020 /PRNewswire/ -- EirGenix, Inc. (6589, TT) had undertaken the transfer of drug substance manufacturing of a marketed drug from a Japanese pharmaceutical company and has since fulfilled all the regulatory requirements necessary to complete the manufacturing site transfer. The ...
2020-02-14 15:14
2847
Sihuan Pharmaceutical Accelerates Product Expansion in Digestive System and Liver Related Diseases
HONG KONG, Feb. 14, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd.(HKEX: 0460) ("Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that the progress achieved by the Group in the research and development of drugs for treati...
2020-02-14 10:35
7521
Immuron reports diarrhea no.1 health issue for Americans on vacation
NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Diarrhea remains the top health issue
facing Americans traveling to high risk countries, affecting 30 to 70 per
cent of travelers depending upon their destination, according to
biopharmaceutical company Immuron Limited[1], [2].
2020-02-13 04:35
1210
GC Pharma Reports Full Year 2019 Results
All consolidated entities revenues grew plus compared to prior year YONGIN, South Korea, Feb. 12, 2020 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended31 December 201...
2020-02-12 22:00
9988
Week's Top Stories
Most Reposted
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
[Picked up by 298 media titles]
2024-12-31 14:18
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
[Picked up by 281 media titles]
2024-12-30 15:33
Interest-Driven Consumption Sparks ¥ 500B ACG Goods Market, MINISO Rides the Wave
[Picked up by 277 media titles]
2025-01-03 19:33
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
[Picked up by 276 media titles]
2025-01-02 08:16
CKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
[Picked up by 258 media titles]
2024-12-31 22:30Most Read
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
2024-12-30 15:33
8705
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
2024-12-31 14:18
8703